{
  "id": "IF13237",
  "type": "In Focus",
  "typeId": "IF",
  "number": "IF13237",
  "active": true,
  "source": "Congress.gov",
  "versions": [
    {
      "source": "Congress.gov",
      "sourceLink": "https://www.congress.gov/crs-product/IF13237",
      "id": "IF13237_A1_2026-05-29",
      "date": "2026-05-29",
      "retrieved": "2026-05-30T06:25:30.873738",
      "title": "Medicare Part B Drugs Overview",
      "summary": null,
      "type": "In Focus",
      "typeId": "IF",
      "active": true,
      "formats": [
        {
          "format": "PDF",
          "url": "https://www.congress.gov/crs_external_products/IF/PDF/IF13237/IF13237.1.pdf",
          "sha1": "897178c155e0c9443797f1d119afff4f475a4a49",
          "filename": "files/2026-05-29_IF13237_897178c155e0c9443797f1d119afff4f475a4a49.pdf"
        },
        {
          "format": "HTML",
          "url": "https://www.congress.gov/crs_external_products/IF/HTML/IF13237.web.html",
          "sha1": "44c17719da659b869e4ca3b0455d630d33f50aea",
          "filename": "files/2026-05-29_IF13237_44c17719da659b869e4ca3b0455d630d33f50aea.html"
        }
      ],
      "source_dir": "crsreports.congress.gov"
    }
  ],
  "topics": []
}